title: [Level of evidence for therapeutic drug monitoring for paclitaxel].
abstract: Paclitaxel is an anticancer drug which displays pharmacokinetic properties which can lead to therapeutic drug monitoring requirement. The most effective pharmacokinetic parameter seems to be the time during which the plasma concentration is over 0.05 micromol/L. However, this target needs to be validated with new weekly schedules of administration. These reasons lead to consider the level of evidence of therapeutic drug monitoring of paclitaxel as potentially useful.
authors.affiliation: CHU Besançon, Laboratoire de Pharmacologie Clinique, Hôpital Jean Minjoz, Inserm, U645, Université de Franche-Comté, Besançon, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Gerritsen-van Schieveen
authors.forename: Bernard
authors.initials: B
authors.lastname: Royer
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel